Celestica Bounces 12% After Earnings, But the Month-Long Damage Remains

CLS delivered a sharp one-day reversal on October 27, climbing 12% to CAD 388.33 after its Q3 earnings release. That bounce follows a brutal run: the stock is still down 25% over the past month and down 8% on the week, a gap that remains wide relative to closest peers.

Short interest is not the story behind that decline, and the data makes that clearer after the print than before it. Shorts have been retreating, not building. Short interest fell 15% over the past week to roughly 1 million shares, or less than 0.9% of the free float. That is a low and falling level by any measure. The lending market confirms the direction: availability has reached the maximum reading in the data, with more than 100 times as many shares available to borrow as are currently shorted. Borrowing costs are nominal at 0.35% annually. There is no speculative short position of consequence sitting in this stock, and whoever sold during the one-month decline was not borrowing shares to do it.

The CEO sales from late September remain the most notable insider data point in the recent record. Robert Mionis sold approximately CAD 4.7 million in shares across multiple transactions on September 23, all executed under a pre-arranged 10b5-1 plan. Planned disposals carry less signal than discretionary ones, but the net insider position across the past 90 days is a net sale of roughly 132,000 shares worth close to USD 48 million. Director-level activity in the same period was limited to small option-exercise and tax-withholding transactions, which are compensation mechanics rather than market views.

On the institutional register, FMR is the largest holder at 6.85% of shares, followed by Vanguard at 3.65% and Franklin Templeton at 2.41%. Among 13D/G filers, Whale Rock Capital has disclosed a reduction from 5.1% to 4.03%, dropping below the threshold at which it would need to file again. BlackRock filed a 5.5% passive stake in January 2026, and FMR's most recent amendment in February 2026 shows a trim from 7.7% to 6.4%. No activist 13D is on file. These disclosures are as-last-reported and stakes can move without a further filing once they fall below 5%.

The ORTEX short score has drifted lower over the past two weeks, from 27.4 on October 14 to 26.6 on October 27, consistent with the reduction in short interest and loosening of the borrow market. Factor rankings place the stock in the 89th percentile on short score rank and the 90th percentile on 90-day EPS momentum, but only the 28th percentile on forward earnings growth. The price-to-earnings multiple came into earnings around 14.9 times, compressing sharply from its 30-day prior level as the stock fell. EV/EBITDA is running near 10.6 times, up about one turn over the past week as the enterprise value recovered with the share price.

The question now is whether the 12% single-day move on earnings fully closes the gap opened by the month-long sell-off, or whether the stock consolidates at a lower range than the peaks it traded at through September. Closest peers PLXS and FN are both down 2% to 3% on the week, while COHR and BHE are up slightly. The positioning data, with shorts at multi-month lows and availability fully open, leaves the next direction determined by the earnings result itself rather than by any mechanical pressure in the lending market.